Investments, Funding & Disinvestment

CSPC is expected to receive an additional USD3.5 billion if the programs successfully meet development and regulatory milestones, in addition to royalties from any drugs approved under the partnership.

This new facility marks Lilly’s fourth major U.S. manufacturing project in recent years and adds to its broader domestic expansion strategy.

Both organizations plan to develop a long-term framework that facilitates knowledge exchange, clinical cooperation, and the joint development of physician training programs.

Kenmare Bio will obtain worldwide development and commercialization rights to an experimental oral small molecule known as FHND5032, with the exception of Greater China, where Chia Tai Feng Hai will retain control.

Eli Lilly will obtain exclusive global rights to advance these programmed recombinases through preclinical studies, clinical development, and eventual commercialization.

The investment will enhance AstraZeneca’s existing manufacturing sites in Wuxi, Beijing, Qingdao, and Taizhou, which already serve patients in China and across 70 international markets.

The new facility promises to revolutionize medical care for residents of Pleebo City and the surrounding communities, who have long endured the burden of traveling significant distances to access surgical services.

The AI-powered system automatically analyzes computed tomography (CT) scans that were originally performed for unrelated medical reasons, identifying osteoporotic pathological signs without requiring additional examinations.

The company will showcase its technology on the ABHI UK Pavilion alongside a robust delegation of UK life sciences and health technology companies.

The strategic focus will center on three key areas: enhancing the product portfolio, accelerating digital transformation and e-commerce capabilities, and driving expansion into regional markets across the Middle East and Africa.